Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy
Brain metastasis (BM) occurs only in about 1% of differentiated thyroid carcinoma (DTC) cases. Although DTC generally has a good prognosis, once BM develops, the mortality rate significantly increases up to 78%. BM is usually treated by surgical resection or external radiotherapy, whereas radioactiv...
Saved in:
Main Authors: | Leo Hashimoto, Shiro Watanabe, Mungunkhuyag Majigsuren, Kenji Hirata, Junki Takenaka, Rina Kimura, Hiroshi Ishii, Kohsuke Kudo |
---|---|
Format: | Article |
Language: | English |
Published: |
Mashhad University of Medical Sciences
2025-07-01
|
Series: | Asia Oceania Journal of Nuclear Medicine and Biology |
Subjects: | |
Online Access: | https://aojnmb.mums.ac.ir/article_25946_879705d895cc7c4aed3b5f5b775725ae.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01) -
A practical approach on radioprotection in the treatment of radioiodine for thyroid cancer
by: Janaína Dutra Silvestre Mendes, et al.
Published: (2018-09-01) -
Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01) -
Labeling Peptides with Radioiodine: An Overview of Traditional and Emerging Techniques
by: Vincenzo Patamia, et al.
Published: (2025-07-01) -
Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis
by: Congcong Wang, et al.
Published: (2025-08-01)